Lipoic acid decreases inflammation and confers neuroprotection in experimental autoimmune optic neuritis

Priya Chaudhary, Gail Marracci, Xiaolin Yu, Danielle Galipeau, Brooke Morris, Dennis Bourdette

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Lipoic acid (LA) is an antioxidant that is effective in treating experimental autoimmune encephalomyelitis (EAE), a model for multiple sclerosis (MS). C57BL/6 mice with EAE develop experimental autoimmune optic neuritis (EAON), which models acute optic neuritis in humans. Here we determined whether LA is therapeutically effective in EAON. We immunized C57BL/6 mice with MOG 35-55 peptide. Mice received either daily subcutaneous injections of LA (100. mg/kg) or saline in early or late suppression paradigms. In the early suppression paradigm, optic nerve cross-sections showed 14.9 ± 3.8% (mean ± SEM) damage in mice receiving saline (n=7) and 2.0 ± 0.4% damage in mice given LA (n=7, p=0.001). In the late suppression paradigm, optic nerve sections showed 24.6 ± 3.5% damage in mice treated with saline (n=7) and 8.4 ± 2.5% in mice treated with LA (n=7, p=0.004). Thus a dramatic reduction in axonal injury was seen after LA administration in both experimental paradigms. Compared with saline treated mice with EAON, optic nerves from mice receiving LA had significantly fewer CD4+ and CD11b+ cells in both paradigms. This study provides a rationale for investigating the therapeutic efficacy of LA in acute optic neuritis in humans.

Original languageEnglish (US)
Pages (from-to)90-96
Number of pages7
JournalJournal of Neuroimmunology
Volume233
Issue number1-2
DOIs
StatePublished - Apr 2011

Fingerprint

Experimental Autoimmune Neuritis
Thioctic Acid
Optic Neuritis
Inflammation
Optic Nerve
Autoimmune Experimental Encephalomyelitis
Inbred C57BL Mouse
Neuroprotection
Subcutaneous Injections
Multiple Sclerosis
Antioxidants
Peptides

Keywords

  • EAON
  • Lipoic acid
  • Multiple sclerosis
  • Neuroprotection
  • Optic neuritis

ASJC Scopus subject areas

  • Immunology
  • Clinical Neurology
  • Immunology and Allergy
  • Neurology

Cite this

Lipoic acid decreases inflammation and confers neuroprotection in experimental autoimmune optic neuritis. / Chaudhary, Priya; Marracci, Gail; Yu, Xiaolin; Galipeau, Danielle; Morris, Brooke; Bourdette, Dennis.

In: Journal of Neuroimmunology, Vol. 233, No. 1-2, 04.2011, p. 90-96.

Research output: Contribution to journalArticle

@article{a4464568700f452f8f85419868957711,
title = "Lipoic acid decreases inflammation and confers neuroprotection in experimental autoimmune optic neuritis",
abstract = "Lipoic acid (LA) is an antioxidant that is effective in treating experimental autoimmune encephalomyelitis (EAE), a model for multiple sclerosis (MS). C57BL/6 mice with EAE develop experimental autoimmune optic neuritis (EAON), which models acute optic neuritis in humans. Here we determined whether LA is therapeutically effective in EAON. We immunized C57BL/6 mice with MOG 35-55 peptide. Mice received either daily subcutaneous injections of LA (100. mg/kg) or saline in early or late suppression paradigms. In the early suppression paradigm, optic nerve cross-sections showed 14.9 ± 3.8{\%} (mean ± SEM) damage in mice receiving saline (n=7) and 2.0 ± 0.4{\%} damage in mice given LA (n=7, p=0.001). In the late suppression paradigm, optic nerve sections showed 24.6 ± 3.5{\%} damage in mice treated with saline (n=7) and 8.4 ± 2.5{\%} in mice treated with LA (n=7, p=0.004). Thus a dramatic reduction in axonal injury was seen after LA administration in both experimental paradigms. Compared with saline treated mice with EAON, optic nerves from mice receiving LA had significantly fewer CD4+ and CD11b+ cells in both paradigms. This study provides a rationale for investigating the therapeutic efficacy of LA in acute optic neuritis in humans.",
keywords = "EAON, Lipoic acid, Multiple sclerosis, Neuroprotection, Optic neuritis",
author = "Priya Chaudhary and Gail Marracci and Xiaolin Yu and Danielle Galipeau and Brooke Morris and Dennis Bourdette",
year = "2011",
month = "4",
doi = "10.1016/j.jneuroim.2010.12.002",
language = "English (US)",
volume = "233",
pages = "90--96",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Lipoic acid decreases inflammation and confers neuroprotection in experimental autoimmune optic neuritis

AU - Chaudhary, Priya

AU - Marracci, Gail

AU - Yu, Xiaolin

AU - Galipeau, Danielle

AU - Morris, Brooke

AU - Bourdette, Dennis

PY - 2011/4

Y1 - 2011/4

N2 - Lipoic acid (LA) is an antioxidant that is effective in treating experimental autoimmune encephalomyelitis (EAE), a model for multiple sclerosis (MS). C57BL/6 mice with EAE develop experimental autoimmune optic neuritis (EAON), which models acute optic neuritis in humans. Here we determined whether LA is therapeutically effective in EAON. We immunized C57BL/6 mice with MOG 35-55 peptide. Mice received either daily subcutaneous injections of LA (100. mg/kg) or saline in early or late suppression paradigms. In the early suppression paradigm, optic nerve cross-sections showed 14.9 ± 3.8% (mean ± SEM) damage in mice receiving saline (n=7) and 2.0 ± 0.4% damage in mice given LA (n=7, p=0.001). In the late suppression paradigm, optic nerve sections showed 24.6 ± 3.5% damage in mice treated with saline (n=7) and 8.4 ± 2.5% in mice treated with LA (n=7, p=0.004). Thus a dramatic reduction in axonal injury was seen after LA administration in both experimental paradigms. Compared with saline treated mice with EAON, optic nerves from mice receiving LA had significantly fewer CD4+ and CD11b+ cells in both paradigms. This study provides a rationale for investigating the therapeutic efficacy of LA in acute optic neuritis in humans.

AB - Lipoic acid (LA) is an antioxidant that is effective in treating experimental autoimmune encephalomyelitis (EAE), a model for multiple sclerosis (MS). C57BL/6 mice with EAE develop experimental autoimmune optic neuritis (EAON), which models acute optic neuritis in humans. Here we determined whether LA is therapeutically effective in EAON. We immunized C57BL/6 mice with MOG 35-55 peptide. Mice received either daily subcutaneous injections of LA (100. mg/kg) or saline in early or late suppression paradigms. In the early suppression paradigm, optic nerve cross-sections showed 14.9 ± 3.8% (mean ± SEM) damage in mice receiving saline (n=7) and 2.0 ± 0.4% damage in mice given LA (n=7, p=0.001). In the late suppression paradigm, optic nerve sections showed 24.6 ± 3.5% damage in mice treated with saline (n=7) and 8.4 ± 2.5% in mice treated with LA (n=7, p=0.004). Thus a dramatic reduction in axonal injury was seen after LA administration in both experimental paradigms. Compared with saline treated mice with EAON, optic nerves from mice receiving LA had significantly fewer CD4+ and CD11b+ cells in both paradigms. This study provides a rationale for investigating the therapeutic efficacy of LA in acute optic neuritis in humans.

KW - EAON

KW - Lipoic acid

KW - Multiple sclerosis

KW - Neuroprotection

KW - Optic neuritis

UR - http://www.scopus.com/inward/record.url?scp=79953326927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953326927&partnerID=8YFLogxK

U2 - 10.1016/j.jneuroim.2010.12.002

DO - 10.1016/j.jneuroim.2010.12.002

M3 - Article

VL - 233

SP - 90

EP - 96

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

IS - 1-2

ER -